Received SEC

APR 2 8 2015 Washington, DC 20549



William Slattery, CFA Vice President Listing Qualifications



Electronic Mail Only

April 28, 2015

Ms. Cecile Peters Chief, IT Services **Division of Corporation Finance** U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Dear Ms. Peters:

By letter dated October 1, 2014, I advised you that the Exchange had received a Form 8-A from Eyegate Pharmaceuticals, Inc. for registration of its Common Stock, par value \$0.01 per share and the Exchange had approved the security for listing and registration upon official notice of issuance.

Since then, we have been advised that the company wishes to withdraw its application to list the security on the Exchange. Accordingly, we hereby withdraw our earlier certification of approval.

Sincerely,

William Lattery

The NASDAQ OMX Group + 805 King Farm Blvd. + Rockville, MD 20850 + USA + www.nasdagomx.com